Cargando…

Abnormal MDMX degradation in tumor cells due to ARF deficiency

MDMX is a hetero dimeric partner of MDM2 and a critical regulator of p53. MDMX level is generally elevated in tumors with wild type p53 and contributes to p53 inactivation. MDMX degradation is controlled in part by MDM2-mediated ubiquitination. Here we show that MDMX turnover is highly responsive to...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaolong, Gilkes, Daniele, Li, Baozong, Cheng, Qian, Pernazza, Daniele, Lawrence, Nicholas, Chen, Jiandong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3290737/
https://www.ncbi.nlm.nih.gov/pubmed/22120712
http://dx.doi.org/10.1038/onc.2011.534
_version_ 1782225039464071168
author Li, Xiaolong
Gilkes, Daniele
Li, Baozong
Cheng, Qian
Pernazza, Daniele
Lawrence, Nicholas
Chen, Jiandong
author_facet Li, Xiaolong
Gilkes, Daniele
Li, Baozong
Cheng, Qian
Pernazza, Daniele
Lawrence, Nicholas
Chen, Jiandong
author_sort Li, Xiaolong
collection PubMed
description MDMX is a hetero dimeric partner of MDM2 and a critical regulator of p53. MDMX level is generally elevated in tumors with wild type p53 and contributes to p53 inactivation. MDMX degradation is controlled in part by MDM2-mediated ubiquitination. Here we show that MDMX turnover is highly responsive to changes in MDM2 level in non-transformed cells, but not in tumor cells. We found that loss of ARF expression, which occurs in most tumors with wild type p53, significantly reduces MDMX sensitivity to MDM2. Restoration of ARF expression in tumor cells enables MDM2 to degrade MDMX in a dose-dependent fashion. ARF binds to MDM2 and stimulates a second-site interaction between the central region of MDM2 and MDMX, thus increases MDMX-MDM2 binding and MDMX ubiquitination. These results reveal an important abnormality in the p53 regulatory pathway as a consequence of ARF deficiency. Loss of ARF during tumor development not only prevents p53 stabilization by proliferative stress, but also causes accumulation of MDMX that compromises p53 activity. This phenomenon may reduce the clinical efficacy of MDM2-specific inhibitors by preventing MDMX down regulation.
format Online
Article
Text
id pubmed-3290737
institution National Center for Biotechnology Information
language English
publishDate 2011
record_format MEDLINE/PubMed
spelling pubmed-32907372013-02-09 Abnormal MDMX degradation in tumor cells due to ARF deficiency Li, Xiaolong Gilkes, Daniele Li, Baozong Cheng, Qian Pernazza, Daniele Lawrence, Nicholas Chen, Jiandong Oncogene Article MDMX is a hetero dimeric partner of MDM2 and a critical regulator of p53. MDMX level is generally elevated in tumors with wild type p53 and contributes to p53 inactivation. MDMX degradation is controlled in part by MDM2-mediated ubiquitination. Here we show that MDMX turnover is highly responsive to changes in MDM2 level in non-transformed cells, but not in tumor cells. We found that loss of ARF expression, which occurs in most tumors with wild type p53, significantly reduces MDMX sensitivity to MDM2. Restoration of ARF expression in tumor cells enables MDM2 to degrade MDMX in a dose-dependent fashion. ARF binds to MDM2 and stimulates a second-site interaction between the central region of MDM2 and MDMX, thus increases MDMX-MDM2 binding and MDMX ubiquitination. These results reveal an important abnormality in the p53 regulatory pathway as a consequence of ARF deficiency. Loss of ARF during tumor development not only prevents p53 stabilization by proliferative stress, but also causes accumulation of MDMX that compromises p53 activity. This phenomenon may reduce the clinical efficacy of MDM2-specific inhibitors by preventing MDMX down regulation. 2011-11-28 2012-08-09 /pmc/articles/PMC3290737/ /pubmed/22120712 http://dx.doi.org/10.1038/onc.2011.534 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Li, Xiaolong
Gilkes, Daniele
Li, Baozong
Cheng, Qian
Pernazza, Daniele
Lawrence, Nicholas
Chen, Jiandong
Abnormal MDMX degradation in tumor cells due to ARF deficiency
title Abnormal MDMX degradation in tumor cells due to ARF deficiency
title_full Abnormal MDMX degradation in tumor cells due to ARF deficiency
title_fullStr Abnormal MDMX degradation in tumor cells due to ARF deficiency
title_full_unstemmed Abnormal MDMX degradation in tumor cells due to ARF deficiency
title_short Abnormal MDMX degradation in tumor cells due to ARF deficiency
title_sort abnormal mdmx degradation in tumor cells due to arf deficiency
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3290737/
https://www.ncbi.nlm.nih.gov/pubmed/22120712
http://dx.doi.org/10.1038/onc.2011.534
work_keys_str_mv AT lixiaolong abnormalmdmxdegradationintumorcellsduetoarfdeficiency
AT gilkesdaniele abnormalmdmxdegradationintumorcellsduetoarfdeficiency
AT libaozong abnormalmdmxdegradationintumorcellsduetoarfdeficiency
AT chengqian abnormalmdmxdegradationintumorcellsduetoarfdeficiency
AT pernazzadaniele abnormalmdmxdegradationintumorcellsduetoarfdeficiency
AT lawrencenicholas abnormalmdmxdegradationintumorcellsduetoarfdeficiency
AT chenjiandong abnormalmdmxdegradationintumorcellsduetoarfdeficiency